Avelumab in gastric cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). • It shows the impact the disease has in the clinical world and how important it is to find an alternative way to better treat the disease.
  MedlineGoogle Scholar
• 2 Niccolai E, Taddei A, Prisco D, Amedei A. Gastric cancer and the epoch of immunotherapy approaches. World J. Gastroenterol. 21, 5778–5793 (2015).
  Medline CASGoogle Scholar
• 3 Kang Y-K, Kang W-K, Shin et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20, 666–673 (2009).
  MedlineGoogle Scholar
• 4 Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).
  Medline CASGoogle Scholar
• 5 Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised Phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer 47, 2306–2314 (2011).
  Medline CASGoogle Scholar
• 6 Kang JH, Lee S Il Lim DH et al. Salvage chemotherapy for pretreated gastric cancer: a randomized Phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 30, 1513–1518 (2012).
  Medline CASGoogle Scholar
• 7 Ford HER, Marshall A, Bridgewater JA et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, Phase 3 randomised controlled trial. Lancet. Oncol. 15, 78–86 (2014).
  Medline CASGoogle Scholar
• 8 Roviello G, Ravelli A, Fiaschi AI et al. Apatinib for the treatment of gastric cancer. Expert Rev. Gastroenterol. Hepatol. 10, 1–6 (2016).
  MedlineGoogle Scholar
• 9 Shitara K, Doi T, Dvorkin M et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 19, 1437–1448 (2018).
  Medline CASGoogle Scholar
• 10 Fuchs CS, Doi T, Jang RW-J et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J. Clin. Oncol. 35, 4003–4003 (2017).
  MedlineGoogle Scholar
• 11 Kang Y-K, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet 390, 2461–2471 (2017).
  Medline CASGoogle Scholar
• 12 Kaufman HL, Russell JS, Hamid O et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J. Immunother. Cancer 6, 7 (2018). •• Data from JAVELIN Merkel 200, which is a Phase II clinical trial on the Merkel cell carcinoma that brought to the US FDA approval of avelumab for Merkel cell carcinoma.
  MedlineGoogle Scholar
• 13 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
  Medline CASGoogle Scholar
• 14 Cheng G, Li M, Wu J et al. Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis. Int. J. Clin. Exp. Pathol. 8, 9452–9457 (2015).
  Medline CASGoogle Scholar
• 15 Takaya S, Saito H, Ikeguchi M. Upregulation of immune checkpoint molecules, PD-1 and LAG-3, on CD4+ and CD8+ T cells after gastric cancer surgery. Yonago Acta Med. 58, 39–44 (2015).
  Medline CASGoogle Scholar
• 16 Kim JW, Nam KH, Ahn S-H et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19, 42–52 (2016).
  Medline CASGoogle Scholar
• 17 Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology 129, 474–481 (2010).
  Medline CASGoogle Scholar
• 18 Dai C, Wang M, Lu J et al. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. Onco. Targets. Ther. 10, 3625–3634 (2017).
  MedlineGoogle Scholar
• 19 Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE 10, e0131403 (2015).
  MedlineGoogle Scholar
• 20 Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).
  Medline CASGoogle Scholar
• 21 Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
  Medline CASGoogle Scholar
• 22 Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98–106 (2016).
  Medline CASGoogle Scholar
• 23 Bass AJ, Thorsson VV, Shmulevich I et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
  MedlineGoogle Scholar
• 24 Chan TA, Yarchoan M, Jaffee E et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30(1), 44–56 (2018).
  Google Scholar
• 25 Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J. Gastrointest. Oncol. 6, 561–569 (2015).
  MedlineGoogle Scholar
• 26 Hato SV, Khong A de Vries IJM, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin. Cancer Res. 20, 2831–2837 (2014).
  Medline CASGoogle Scholar
• 27 Bass AJ, Thorsson V, Shmulevich I et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
  MedlineGoogle Scholar
• 28 Togasaki K, Sukawa Y, Kanai T, Takaishi H. Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. Onco. Targets. Ther. 11, 8239–8250 (2018).
  Medline CASGoogle Scholar
• 29 Boyerinas B, Jochems C, Fantini M et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res. 3, 1148–1157 (2015).
  Medline CASGoogle Scholar
• 30 Grenga I, Donahue RN, Lepone LM, Richards J, Schlom J. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin. Transl. Immunol. 5, e83 (2016).
  MedlineGoogle Scholar
• 31 Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
  Medline CASGoogle Scholar
• 32 Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122 (2007).
  Medline CASGoogle Scholar
• 33 Brown JA, Dorfman DM, Ma F-R et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266 (2003).
  Medline CASGoogle Scholar
• 34 Sarabipour S, Hristova K. Mechanism of FGF receptor dimerization and activation. Nat. Commun. 7, 10262 (2016).
  Medline CASGoogle Scholar
• 35 Liu K, Tan S, Chai Y et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 27, 151–153 (2017).
  Medline CASGoogle Scholar
• 36 Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).
  Medline CASGoogle Scholar
• 37 Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 34, 556–563 (2013).
  Medline CASGoogle Scholar
• 38 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
  Medline CASGoogle Scholar
• 39 Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).
  Medline CASGoogle Scholar
• 40 Riley JL. PD-1 signaling in primary T cells. Immunol. Rev. 229, 114–125 (2009).
  Medline CASGoogle Scholar
• 41 Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
  Medline CASGoogle Scholar
• 42 Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
  Medline CASGoogle Scholar
• 43 Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl. lung cancer Res. 4, 743–751 (2015).
  Medline CASGoogle Scholar
• 44 Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001).
  Medline CASGoogle Scholar
• 45 Tseng SY, Otsuji M, Gorski K et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839–846 (2001).
  Medline CASGoogle Scholar
• 46 Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34, 539–573 (2016).
  Medline CASGoogle Scholar
• 47 Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5, 915–919 (2015).
  Medline CASGoogle Scholar
• 48 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
  Medline CASGoogle Scholar
• 49 Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. NY Acad. Sci. 1217, 45–59 (2011).
  Medline CASGoogle Scholar
• 50 Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219–242 (2010).
  Medline CASGoogle Scholar
• 51 Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19, 813–824 (2007).
  Medline CASGoogle Scholar
• 52 Li Y, Li F, Jiang F et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int. J. Mol. Sci. 17, 1151 (2016).
  MedlineGoogle Scholar
• 53 Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467–477 (2008).
  Medline CASGoogle Scholar
• 54 Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).
  Medline CASGoogle Scholar
• 55 Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029 (2009).
  Medline CASGoogle Scholar
• 56 Sheppard K-A, Fitz LJ, Lee JM et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett. 574, 37–41 (2004).
  Medline CASGoogle Scholar
• 57 Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
  Medline CASGoogle Scholar
• 58 Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu. Rev. Immunol. 23, 515–548 (2005).
  MedlineGoogle Scholar
• 59 Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation Cell. 4 144(5), 646–674 (2011).
  CASGoogle Scholar
• 60 Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317–327 (2010).
  Medline CASGoogle Scholar
• 61 Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer. Cancer J. 20, 281–289 (2014).
  Medline CASGoogle Scholar
• 62 Herbst RS, Soria J-C, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
  Medline CASGoogle Scholar
• 63 Donahue RN, Lepone LM, Grenga I et al. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J. Immunother. Cancer 5, 20 (2017).
  MedlineGoogle Scholar
• 64 Gaiser MR, Bongiorno M, Brownell I. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Rev. Clin. Pharmacol. 11, 345–359 (2018).
  Medline CASGoogle Scholar
• 65 US FDA. Information., E.S.I. and P.I.B. (avelumab) injection: U. (2017). www.fda.gov
  Google Scholar
• 66 Heery CR, O'Sullivan-Coyne G, Madan RA et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 18, 587–598 (2017). •• Results from the JAVELIN in Solid Tumors Phase Ia dose-escalation clinical trial.
  Medline CASGoogle Scholar
• 67 Chung HC, Arkenau H-T, Lee J et al. Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer 7, 30 (2019).
  MedlineGoogle Scholar
• 68 Doi T, Iwasa S, Muro K et al. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer (2018). (Epub ahead of print). •• Results of avelumab in Japanese patients with advanced gastric cancer Phase Ib clinical trial.
  Google Scholar
• 69 Bang Y-J, Ruiz EY, Van Cutsem E et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann. Oncol. 29, 2052–2060 (2018). •• Results of the JAVELIN Gastric 300.
  MedlineGoogle Scholar
• 70 Moehler M, Ryu M-H, Dvorkin M et al. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. Future Oncol. fon-2018-0668 (2018). •• The design of the latest large clinical trial testing avelubam maintenance therapy versus continuation of first-line chemotherapy.
  MedlineGoogle Scholar
• 71 Kelly K, Infante JR, Taylor MH et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer 124, 2010–2017 (2018).
  Medline CASGoogle Scholar
• 72 Dreyer NA. Advancing a framework for regulatory use of real-world evidence. Ther. Innov. Regul. Sci. 52, 362–368 (2018). •• The safety profile of avelumab in patients with advanced solid tumors.
  MedlineGoogle Scholar
• 73 Stenger M. Avelumab in locally advanced or metastatic urothelial carcinoma – the ASCO Post. (2018). www.ascopost.com/issues/october-10-2017/avelumab-in-locally-advanced-or-metastatic-urothelial-carcinoma/
  Google Scholar
• 74 FDA; CDER. Highlights of prescribing information. www.fda.gov/Drugs/default.htm
  Google Scholar
• 75 Capitani N, Codolo G, Vallese F et al. The lipoprotein HP1454 of Helicobacter pylori regulates T-cell response by shaping T-cell receptor signalling. Cell. Microbiol. e13006 (2019).
  MedlineGoogle Scholar
• 76 Hellmann MD, Ciuleanu T-E, Pluzanski A et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
  Medline CASGoogle Scholar